Tesamorelin and HIV Lipodystrophy

Tesamorelin

15.2% visceral fat reduction

In the landmark phase III trial, tesamorelin reduced visceral adipose tissue by 15.2% over 26 weeks in HIV patients with abdominal fat accumulation, versus a 5.0% increase with placebo.

Falutz et al., NEJM, 2007

Falutz et al., NEJM, 2007

View as image

Antiretroviral therapy turned HIV from a death sentence into a manageable chronic condition. It also created a new medical problem: lipodystrophy, a disfiguring redistribution of body fat that affects 20-35% of people on long-term HIV treatment. Fat accumulates in the abdomen, around the organs, and sometimes behind the neck, while simultaneously disappearing from the face, limbs, and buttocks. Beyond the cosmetic impact, visceral fat accumulation increases cardiovascular risk, worsens insulin resistance, and drives metabolic syndrome in a population already managing a complex disease. Tesamorelin, a synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH), was specifically developed to solve this problem. It remains the only FDA-approved treatment for HIV-associated lipodystrophy.^[1] For tesamorelin's broader pharmacology, see Tesamorelin (Egrifta): The FDA-Approved GHRH Analog.

What Is HIV-Associated Lipodystrophy?

HIV-associated lipodystrophy is not a single condition but a spectrum of body fat changes driven by antiretroviral medications, the virus itself, and chronic immune activation. Two patterns coexist, often in the same patient:

Lipoatrophy: loss of subcutaneous fat from the face (sunken cheeks), extremities, and buttocks. This was more common with older nucleoside reverse transcriptase inhibitors (NRTIs) like stavudine and zidovudine, and its prevalence has decreased with newer drug regimens.

Lipohypertrophy: abnormal accumulation of visceral adipose tissue (VAT) in the abdomen, dorsocervical fat pad ("buffalo hump"), and breast tissue. This pattern persists with current antiretroviral regimens and is the primary target of tesamorelin therapy.

The metabolic consequences of visceral fat accumulation are substantial. Visceral fat is metabolically active tissue that secretes inflammatory cytokines, worsens insulin resistance, and increases cardiovascular risk independently of total body fat. HIV-positive individuals with lipodystrophy have higher rates of diabetes, dyslipidemia, and cardiovascular events than those without it.

Jain et al. (2013) reviewed the pathophysiology of the GHRH-growth hormone-IGF1 axis in HIV/AIDS, documenting how HIV infection and antiretroviral therapy both disrupt normal growth hormone signaling. Protease inhibitors in particular can alter GH secretion patterns and promote visceral fat deposition. This axis disruption provides the biological rationale for tesamorelin: restoring physiologic GH secretion through GHRH stimulation corrects the specific hormonal deficiency driving fat redistribution. Unlike empirical treatments that target symptoms, tesamorelin addresses a defined pathophysiological mechanism, which is part of why it succeeded where other approaches to HIV lipodystrophy failed.^[4]

The Landmark NEJM Trial: Falutz 2007

The trial that established tesamorelin's efficacy was published in the New England Journal of Medicine in December 2007. Falutz and colleagues enrolled 412 HIV-positive patients (86% male) with clinical evidence of abdominal fat accumulation and randomized them 2:1 to tesamorelin 2 mg or placebo via daily subcutaneous injection for 26 weeks.^[1]

The primary endpoint was change in visceral adipose tissue measured by CT scan at the L4-L5 vertebral level, the gold standard for quantifying abdominal fat distribution.

Results were unambiguous:

• Visceral fat: decreased 15.2% with tesamorelin, increased 5.0% with placebo
• Triglycerides: decreased 50 mg/dL with tesamorelin, increased 9 mg/dL with placebo
• Total cholesterol/HDL ratio: improved with tesamorelin
• Trunk fat: decreased selectively in the visceral compartment
• Subcutaneous fat: not significantly changed (an important finding, since lipoatrophy was already a concern)

The selectivity of the fat reduction was clinically important. Tesamorelin reduced visceral fat without worsening peripheral fat loss, a critical consideration for patients already dealing with lipoatrophy. Glucose and insulin levels were not significantly affected, alleviating concerns that GH stimulation might worsen insulin resistance.

Adverse events were mild: injection site reactions (redness, pain, itching) were the most common. Joint pain and extremity swelling occurred more frequently with tesamorelin but were generally manageable. No clinically significant changes in fasting glucose or HbA1c were observed, which was an important finding given that growth hormone is known to antagonize insulin signaling. The IGF-1 levels increased as expected (confirming that the GHRH stimulation was producing its intended biological effect) but remained within physiologic ranges for most patients.

Phase III Confirmatory Data: Falutz 2010

A second phase III trial, published in AIDS in 2010, confirmed the NEJM findings with a safety extension. Falutz and colleagues randomized 404 patients to tesamorelin or placebo for 26 weeks, then re-randomized the tesamorelin responders to continue treatment or switch to placebo for an additional 26 weeks.^[5]

The results replicated the original trial: significant visceral fat reduction with tesamorelin versus placebo. The extension phase revealed a critical finding: patients who stopped tesamorelin after 26 weeks experienced visceral fat reaccumulation, returning toward baseline levels. This mirrored what the SURMOUNT-4 trial later showed for tirzepatide in obesity: the drug works as long as you take it. For how weight maintenance works with other peptide drugs, see Semaglutide Weight Regain: What the Studies Show After Discontinuation.

Meta-Analysis: Pooling All the Evidence

A 2026 meta-analysis pooling five randomized controlled trials of tesamorelin in HIV-associated lipodystrophy confirmed the drug's efficacy with greater statistical power. Across all trials, tesamorelin reduced visceral adipose tissue by a mean of 27.71 cm squared on CT measurement (95% CI: -38.37 to -17.06; p<0.001) compared to placebo.^[2]

The meta-analysis also confirmed that tesamorelin improved IGF-1 levels (the downstream mediator of growth hormone effects), lean body mass, and hepatic fat content without significant perturbation of glucose homeostasis. Stanley et al. (2012) had earlier shown that the degree of visceral fat reduction correlated directly with metabolic improvements: patients who achieved clinically meaningful visceral fat loss experienced greater reductions in triglycerides and improvements in lipid profiles than non-responders.^[7] The safety profile was consistent across trials, with no new safety signals emerging from the pooled analysis.

Beyond Visceral Fat: Muscle and Metabolic Effects

Stanley et al. (2019) expanded the picture of tesamorelin's body composition effects. In a study published through analysis of CT scans from the phase III trials, tesamorelin decreased intramuscular fat (fat deposits within and between muscle fibers) and increased total muscle area at the thigh level in adults with HIV.^[3]

Intramuscular fat infiltration is associated with insulin resistance and reduced physical function, and its reduction suggests benefits beyond what visceral fat measurement alone captures. The increase in muscle area is consistent with growth hormone's known anabolic effects on skeletal muscle.

Makimura et al. (2014) examined tesamorelin's effects on phosphocreatine recovery in obese subjects with reduced growth hormone secretion. Phosphocreatine recovery rate measured by magnetic resonance spectroscopy reflects mitochondrial function in muscle. Tesamorelin improved recovery rates, suggesting that GH axis restoration may improve muscle energy metabolism in addition to altering fat distribution.^[6]

How Tesamorelin Works: The GHRH Mechanism

Tesamorelin is a modified version of human GHRH (growth hormone-releasing hormone), the 44-amino-acid peptide produced by the hypothalamus that signals the pituitary gland to release growth hormone. The modification (a trans-3-hexenoic acid group attached to the tyrosine at position 1) protects the peptide from enzymatic degradation and extends its half-life enough for once-daily dosing.

Unlike recombinant growth hormone (which bypasses the pituitary and delivers supraphysiologic GH levels), tesamorelin stimulates endogenous GH production. This means the body's normal feedback mechanisms remain intact: GH is released in pulses that mimic the natural pattern, and excess stimulation is self-limiting through negative feedback. This is the same principle behind other GHRH analogs like CJC-1295 and sermorelin, though tesamorelin is the only one with FDA approval for a specific clinical indication.

The distinction matters clinically. Exogenous GH injections suppress the pituitary's own GH production through negative feedback, and long-term use carries risks of acromegaly-like side effects. Tesamorelin's GHRH-mediated approach avoids this problem because the pituitary retains its ability to modulate GH output based on the body's needs.

The released growth hormone then acts on adipose tissue through multiple pathways:

• Increased lipolysis (fat breakdown) in visceral adipocytes
• Reduced lipogenesis (new fat synthesis)
• Increased IGF-1 production, which promotes lean tissue maintenance
• Improved triglyceride clearance from the bloodstream

Tesamorelin's Limitations

Despite being the only FDA-approved treatment for this condition, tesamorelin has notable limitations:

Treatment must continue indefinitely. Visceral fat reaccumulates when tesamorelin is stopped. This makes it a management tool, not a cure, and raises questions about lifetime cost and adherence.

It does not reverse lipoatrophy. Tesamorelin addresses visceral fat accumulation (lipohypertrophy) but does not restore subcutaneous fat lost from the face and extremities. Patients with both patterns of lipodystrophy may need additional interventions (such as facial fillers for lipoatrophy) alongside tesamorelin.

Narrow approved indication. Despite evidence of efficacy for visceral fat reduction, tesamorelin is only FDA-approved for HIV-associated lipodystrophy. Its potential applications in MASH (metabolic dysfunction-associated steatohepatitis) and cognitive decline are under investigation but not yet approved. For the liver fat research, see Tesamorelin and Liver Fat: MASH Research Beyond Its Approved Use.

Cost. Tesamorelin (brand name Egrifta) carries a high price point that limits access. The 2024 FDA approval of Egrifta WR (the F8 formulation) reduced preparation burden by allowing weekly instead of daily reconstitution, but the drug cost remains substantial. For many patients, insurance coverage is inconsistent and prior authorization requirements add barriers to access.

IGF-1 elevation concerns. Long-term IGF-1 elevation carries a theoretical cancer risk, though no increased cancer incidence has been observed in clinical trials. Monitoring IGF-1 levels is recommended during treatment.

The Broader Context: Why This Drug Matters

Tesamorelin's significance extends beyond HIV medicine. It represents the proof of concept that a GHRH analog can selectively reduce visceral fat in a clinical population, with FDA approval and robust clinical trial data supporting it. This distinguishes tesamorelin from the many GH-axis peptides (CJC-1295, ipamorelin, GHRP-6) that circulate in research and anti-aging contexts without equivalent evidence.

The drug also illustrates a broader principle in peptide therapeutics: that working through the body's own signaling pathways (stimulating endogenous GH release rather than injecting exogenous GH) can produce more physiologic effects with fewer side effects. For how tesamorelin's cognitive findings are being explored, see Tesamorelin's Cognitive Effects: An Unexpected Finding.

The Bottom Line

Tesamorelin was developed specifically for HIV-associated lipodystrophy, a disfiguring and metabolically dangerous side effect of antiretroviral therapy. Phase III trials demonstrated 15-20% reductions in visceral adipose tissue with simultaneous improvements in triglycerides, muscle composition, and liver fat. It remains the only FDA-approved GHRH analog and the only approved treatment for this condition. Key limitations include the need for indefinite treatment, inability to reverse peripheral fat loss, and high cost. Its success validates the GHRH-stimulation approach to selective visceral fat reduction.

Frequently Asked Questions

What is tesamorelin used for?

Tesamorelin (brand name Egrifta) is FDA-approved for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary to release growth hormone, which then promotes visceral fat breakdown. In clinical trials, it reduced visceral fat by 15-20% over 26 weeks (Falutz et al., NEJM, 2007). It is the only FDA-approved treatment for this condition.

How much visceral fat does tesamorelin reduce?

In the landmark phase III trial, tesamorelin reduced visceral adipose tissue by 15.2% over 26 weeks, while placebo resulted in a 5.0% increase (Falutz et al., NEJM, 2007). A meta-analysis of five RCTs found an average reduction of approximately 28 cm squared on CT measurement. Triglycerides also decreased by 50 mg/dL. The effect is selective: visceral fat decreases while subcutaneous fat is not significantly affected.

Does tesamorelin work for non-HIV patients?

Tesamorelin is only FDA-approved for HIV-associated lipodystrophy. Research is ongoing for MASH (metabolic liver disease) and cognitive decline in HIV, but these uses are not approved. Makimura et al. (2014) studied tesamorelin in obese non-HIV subjects with reduced growth hormone and found improved muscle energy metabolism, suggesting potential applications beyond HIV, though no approval exists for these uses.

What happens when you stop tesamorelin?

Visceral fat reaccumulates when tesamorelin is discontinued. In the phase III extension study, patients who stopped tesamorelin after 26 weeks of successful treatment saw their visceral fat return toward pre-treatment levels over the following 26 weeks (Falutz et al., AIDS, 2010). This means tesamorelin works as a chronic management tool, not a one-time fix.

Is tesamorelin the same as growth hormone?

No. Tesamorelin is a GHRH analog that stimulates the pituitary gland to release its own growth hormone naturally, maintaining the body's feedback mechanisms. Recombinant growth hormone (somatropin) bypasses the pituitary and delivers GH directly, often at supraphysiologic levels. Tesamorelin produces more physiologic, pulsatile GH release with fewer side effects than direct GH injection. Both raise IGF-1 levels, but through different mechanisms.

What are the side effects of tesamorelin?

The most common side effects in clinical trials were injection site reactions (redness, pain, itching), joint pain, and extremity swelling. Gastrointestinal symptoms occurred in some patients. Tesamorelin raises IGF-1 levels, which requires monitoring due to a theoretical long-term cancer risk, though no increased cancer incidence was observed in trials. Glucose levels were not significantly worsened, an important finding given concerns about growth hormone's effects on insulin sensitivity.